Financial OutlookDynavax's financial future looks promising with expectations to achieve a positive cash flow position, backed by consistent sales performance and reinforced revenue guidance for the coming year.
Product SalesHeplisav-B sales are seeing a significant uptick, with a reported 10% year-over-year increase and a strong foothold in the U.S. market, possessing around 41% market share.
Regulatory MilestoneThe supplemental Biologics License Application for Heplisav-B is currently under priority review by the FDA, which could potentially broaden its market reach.